Many biotech investors have been closely watching the upcoming PDUFA date for DM-1796, DepoMed’s (DEPO) investigational extended-release gabapentin formulation. Depomed’s story has been marred with ups and downs, panicking those investors with a faint heart and forcing weak hands to exit, while the major funds continue to accumulate shares. To understand DM-1796’s approvability and its […]
Finding Opportunity in Abbott – Depomed Dispute
Tuesday, Depomed (DEPO) announced that Abbott (ABT) is disputing elements of their contract regarding DM-1796, an investigational extended-release gabapentin formulation. According to the conference call and press release, CEO Carl Pelzel is “perplexed” by Abbott’s last minute maneuvers and expressed haste in beginning the mediation process and, if needed, binding arbitration. Issues with the contract The issues are […]
News Stories Miss the Point as Depomed Approaches FDA Target Date
Depomed (NASDAQ:DEPO), a specialty pharmaceutical company, has seen a healthy gain in its stock price due in part to its upcoming PDUFA date for DM-1796, a once-a-day treatment for Post Herpetic Neuralgia. Depomed is a unique company, not only because it has compelling product candidates in its pipeline, but also because its platform technology can […]
Investment Opportunities in Women’s Health
The next several months will be an exciting time for the women’s health space, with several important events that may represent an opportunity for investors. Most notably, Pfizer (PFE) has completed data collection for it’s 2186-patient study of Pristiq for the treatment of vasomotor symptoms, more commonly known as hot flashes. Wyeth, now part of […]
Serada Half Price Sale: DepoMed’s Stock Price Poised to Climb
Several weeks ago, DepoMed (NASDAQ:DEPO), a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia (‘PHN’) with DM1796. But DepoMed’s news of success was soon eclipsed. Only one week later, the company announced that Serada didn’t meet its primary endpoints in two pivotal Phase 3 clinical trials for […]
Depomed’s new Parkinson’s drug shows promise
Depomed (NASDAQ:DEPO), a specialty pharmaceutical company, reported positive updates in it’s most recent 10Q regarding it’s phase 1 clinical trial for the treatment of Parkinson’s disease with DM-1992, a novel sustained-release formulation of LevoDopa/Carbidopa. According to the company’s 10Q, Depomed completed the study in early August of 2009. “In the study, DM-1992 extended coverage above […]
Merck beefing up diabetes pipeline
Merck acquires non-exclusive license for Acuform technology from Depomed Merck plans to use technology to expand it’s diabetes portfolio Signifies the extended release diabetes market is growing more competitive Pharmaceutical pipeline weaknesses will spur more deals. Today, Merck (NYSE:MRK) signaled that it will be expanding it’s diabetes pipeline. Merck announced that it has licensed certain […]
Women’s Health: Who can handle the heat for Hot Flashes?
After the Women’s Health Initiative there is an opportunity for new non-hormonal treatments for menopausal symptoms Some estimates believe this market may be up to $8 Billion USD Before the Women’s Health Initiative (‘WHI’), women were effectively treating their menopausal symptoms with hormone replacement therapy (‘HRT’), such as Premarin, Prempro and others. But since then, […]
DepoMed: Protected by Cash and Headed Higher
Recently, my partner has made some great stock picks for his portfolio. The markets now are truly once in a lifetime and these sort of gyrations can present huge opportunities to us small time investors. His portfolio is up 75% month-over-month. I got to give him props. But let me make a case for Depomed (NASDAQ:DEPO). […]
